$TRAW

Traws Pharma (TRAW) has announced a 15-day delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company attributes this delay to recurring operating losses, ongoing efforts to secure financing to meet Nasdaq listing requirements, and the need for KPMG LLP to complete audit procedures following management's going-concern assessment. Despite the delay, Traws Pharma provided preliminary financial results for 2025, projecting $2.8 million in revenue and a net income of approximately $9.2 million.